Displacement of Bim From Anti-Apoptotic Proteins Is the Primary Factor for Determining ABT-737 Activity in Multiple Myeloma Cell Lines.

被引：0
|
作者：
Morales, Alejo A. [1 ]
Kurtoglu, Metin [2 ]
Siefker, David [1 ]
Matulis, Shannon M. [2 ]
Gutman, Delia M. [1 ]
Boise, Lawrence H. [2 ]
机构：
[1] Univ Miami, Miller Sch Med, Miami, FL 33136 USA
[2] Emory Univ, Sch Med, Atlanta, GA USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1113 / 1113
页数：1
相关论文
共 20 条
  • [1] ABT-737 activity on primary multiple myeloma samples
    Ricciardi, M. R.
    Gregorj, C.
    De Cave, F.
    Calabrese, E.
    Santinelli, S.
    Federico, V.
    Bergamo, P.
    Decandia, S.
    Milella, M.
    Foa, R.
    Tafuri, A.
    Petrucci, M. T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 393 - 393
  • [2] ABT-737 synergizes with bortezomib to kill melanoma cells by neutralizing multiple anti-apoptotic defenses
    Shellman, Y. G.
    Partyka, K. A.
    Reuland, S.
    Luo, Y.
    Goldstein, N. B.
    Smith, S.
    Fujita, M.
    Gonzalez, R.
    Lewis, K.
    Norris, D. A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2010, 130 : S57 - S57
  • [3] Pro-apoptotic activity of the BCL-2 inhibitor ABT-737 on primary multiple myeloma samples
    Ricciardi, M. R.
    Gregorj, C.
    De Cave, F.
    Calabrese, E.
    Santinelli, S.
    Federico, V.
    Bergamo, P.
    Milella, M.
    Foa, R.
    Tafuri, A.
    Petrucci, M. T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 145 - 145
  • [4] ABT-737 synergizes with Paclitaxel and Bortezomib to kill melanoma cells by neutralizing multiple anti-apoptotic defenses
    Shellman, Y. G.
    Goldstein, N. B.
    Miller, L. A.
    Smith, S.
    Fujita, M.
    Norris, D. A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2009, 129 : S52 - S52
  • [5] Bak Binding to Bel-x, and Not to Mel-1 Is Associated with ABT-737 Sensitivity in Multiple Myeloma Cell Lines
    Morales, Alejo A.
    Siefker, David
    Matulis, Shannon M.
    Gutman, Delia M.
    Boise, Lawrence H.
    BLOOD, 2008, 112 (11) : 1259 - 1259
  • [6] Functional effects of the Bcl-2/Bcl-xL inhibitor ABT-737 on primary cells from smoldering multiple myeloma
    Ricciardi, Maria Rosaria
    Calabrese, Elisabetta
    De Cave, Fabiana
    Santinelli, Sara
    Bergamo, Paola
    Decandia, Samantha
    Gregorj, Chiara
    Federico, Vincenzo
    Milella, Michele
    Foa, Robert
    Tafuri, Agostino
    Petrucci, Maria Teresa
    BLOOD, 2007, 110 (11) : 269B - 269B
  • [7] Targeting BH3-domain anti-apoptotic proteins with ABT-737 decreases DNA synthesis, induces cell death and sensitizes rituximab-sensitive and rituximab-resistant non-Hodgkin's lymphoma cell lines to the anti-tumor activity of chemotherapy agents
    Vinjamaram, Sanjay
    Hemandez-Ilizaliturri, Francisco J.
    Retke, Steve
    Knight, Joy
    Czuczman, Myron S.
    BLOOD, 2007, 110 (11) : 418A - 418A
  • [8] ABT-737 and erufosine combination against castration-resistant prostate cancer: a promising but cell-type specific response associated with the modulation of anti-apoptotic signaling
    Abdik, Ezgi Avsar
    Kaleagasioglu, Ferda
    Abdik, Hueseyin
    Sahin, Fikrettin
    Berger, Martin R.
    ANTI-CANCER DRUGS, 2019, 30 (04) : 383 - 393
  • [9] FUNCTIONAL EFFECTS OF THE BCL-2/BCL-XL INHIBITOR ABT-737 ON PRIMARY CELLS FROM SMOLDERING AND SYMPTOMATIC MULTIPLE MYELOMA
    Libotte, F.
    Ricciardi, M. R.
    Calabrese, E.
    Santinelli, S.
    Bergamo, P.
    Decandia, S.
    De, Cave F.
    Gregorj, C.
    Federico, V
    Milella, M.
    Foa, R.
    Tafuri, A.
    Petrucci, M. T.
    HAEMATOLOGICA, 2008, 93 : S115 - S115
  • [10] Expression and functional activity of CD52 antigen on primary plasma cells and multiple myeloma cell lines.
    Carlo-Stella, C
    Di Nicola, M
    Longoni, P
    Milanesi, M
    Milani, R
    Carrabba, M
    Gianni, AM
    Corradini, P
    BLOOD, 2003, 102 (11) : 890A - 890A
12